deltatrials
Recruiting PHASE1 INTERVENTIONAL 4-arm NCT07099989

Pharmacokinetics of GATE-251 in Fasted or Fed State

A Randomized, Open-Label, 2-Cohort, 2-Period Crossover Study to Evaluate the Pharmacokinetics of GATE-251 (Zelquistinel), 3 and 10 mg, Under Both Fasted and Fed Conditions in Healthy Adult Participants

Sponsor: Dr. Vince Clinical Research

Conditions Healthy Volunteers in Fed and Fasted State
Interventions Zelquistinel 10 mg Zelquistinel 3 mg
Updated 2 times since 2025 Last updated: Dec 11, 2025 Started: Jul 24, 2025 Primary completion: Jan 31, 2026 Completion: Feb 28, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Healthy Volunteers in Fed and Fasted State and is currently actively recruiting participants. Dr. Vince Clinical Research leads this study, which shows 2 recorded versions since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Sep 2025 – ~Jan 2026 · 4 months · monthly snapshotRecruiting~Jan 2026 – present · 6 months · monthly snapshotRecruiting

Change History

2 versions recorded

  1. Jan 2026 — Present [monthly]

    Recruiting PHASE1

  2. Sep 2025 — Jan 2026 [monthly]

    Recruiting PHASE1

    First recorded

Jul 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Dr. Vince Clinical Research
  • Syndeio Biosciences, Inc
Data source: Syndeio Biosciences, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations